On Invalid Date, Roivant Sciences (NASDAQ: ROIV) reported Q4 2023 earnings per share (EPS) of $6.37, up 1,400% year over year. Total Roivant Sciences earnings for the quarter were $5.10 billion. In the same quarter last year, Roivant Sciences's earnings per share (EPS) was -$0.49.
As of Q1 2024, Roivant Sciences's earnings has grown year over year. Roivant Sciences's earnings in the past year totalled $4.47 billion.
What was ROIV's revenue last quarter?
On Invalid Date, Roivant Sciences (NASDAQ: ROIV) reported Q4 2023 revenue of $37.14 million up 117.8% year over year. In the same quarter last year, Roivant Sciences's revenue was $17.05 million.
What was ROIV's revenue growth in the past year?
As of Q1 2024, Roivant Sciences's revenue has grown 185.76% year over year. This is 20.15 percentage points higher than the US Biotechnology industry revenue growth rate of 165.61%. Roivant Sciences's revenue in the past year totalled $123.24 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.